GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Cyclically Adjusted FCF per Share

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Cyclically Adjusted FCF per Share : $0.18 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Clinuvel Pharmaceuticals's adjusted free cash flow per share data for the fiscal year that ended in Jun. 2023 was $0.465. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.18 for the trailing ten years ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Clinuvel Pharmaceuticals was 55.70% per year. The lowest was -3.60% per year. And the median was 16.40% per year.

As of today (2024-04-30), Clinuvel Pharmaceuticals's current stock price is $ 9.995. Clinuvel Pharmaceuticals's Cyclically Adjusted FCF per Share for the fiscal year that ended in Jun. 2023 was $0.18. Clinuvel Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 55.53.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Clinuvel Pharmaceuticals was 865.20. The lowest was 49.41. And the median was 116.12.


Clinuvel Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.01 0.03 0.11 0.18

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.11 - 0.18 -

Competitive Comparison of Clinuvel Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Clinuvel Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Clinuvel Pharmaceuticals's adjusted Free Cash Flow per Share data for the fiscal year that ended in Jun. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.465/124.1700*124.1700
=0.465

Current CPI (Jun. 2023) = 124.1700.

Clinuvel Pharmaceuticals Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.116 98.352 -0.146
201506 -0.081 99.838 -0.101
201606 -0.084 100.859 -0.103
201706 0.148 102.809 0.179
201806 0.176 104.945 0.208
201906 0.255 106.617 0.297
202006 0.182 106.246 0.213
202106 0.275 110.332 0.309
202206 0.535 117.112 0.567
202306 0.465 124.170 0.465

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Clinuvel Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=9.995/0.18
=55.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Clinuvel Pharmaceuticals was 865.20. The lowest was 49.41. And the median was 116.12.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Clinuvel Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-10-2022

US FDA Review for SCENESSE® Extended by Three Months

By Marketwired Marketwired 06-03-2019

CLINUVEL to Trial Innovative Drug in Stroke

By Marketwired Marketwired 10-28-2020

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-30-2022

CLINUVEL Opens VALLAURIX R&D Centre In Singapore

By Marketwired Marketwired 08-31-2020

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-19-2022

SCENESSE® to be Prescribed in China

By Marketwired Marketwired 04-23-2020

3 High-Performing Stocks

By Alberto Abaterusso Alberto Abaterusso 07-12-2019